Genzyme, a long-time investor in the gene therapy field, has committed to pay Voyager Therapeutics US$100 M upfront to collaborate on the development and commercialisation of the start-up’s pipeline of adeno-associated virus (AAV)-based gene therapies for severe CNS disorders, including Parkinson’s disease, Friedreich’s ataxia and Huntington’s disease. The deal is something of a coup for Voyager, which was launched in February 2014 by Third Rock Ventures with US$45 M in Series A financing.